Skip Navigation


JAC Advance Access originally published online on July 29, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/3/525    most recent
dkg350v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verhaegen, J.
Right arrow Articles by Verbist, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Verhaegen, J.
Right arrow Articles by Verbist, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 525
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Reply

J. Verhaegen1,*, W. Peetermans2 and L. Verbist1

Department of 1 Microbiology and 2 Internal Medicine, University Hospitals Leuven, Department of Microbiology, B-3000 Leuven, Belgium

Keywords: Streptococcus pneumoniae, breakthrough bacteraemia, macrolides, resistance

The first 10% of the full text of this article appears below.

Sir,

Our study1 is retrospective but not anecdotal. Our starting question was: what is the reason behind the failure of initial therapy in patients with invasive pneumococcal infection? In order to give any therapy a fair chance, our cut-off point was treatment for more than 48 h, which left . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?